Literature DB >> 23652877

Significant response to oral Etoposide in the treatment of an unresectable cardiac sarcoma.

Chelsea L Collins1, Peter J Bartz, David R Lal, Annette D Segura, Ronald K Woods, Richard L Tower.   

Abstract

Primary cardiac sarcomas are rare and carry a poor prognosis. The standard of care is complete resection. Outcomes for patients without complete resection are dismal, and the benefit of adjuvant therapy is uncertain. A 9-year-old girl presented with a large right-sided cardiac mass. After biopsy, the tumor was classified as an undifferentiated sarcoma. Resection was not feasible due to apparent invasion of the right ventricle and atrioventricular groove. Treatment with oral etoposide resulted in a 97% reduction in tumor volume and allowed for complete resection of residual tumor. She is alive with no evidence of disease 25 months from diagnosis.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 23652877      PMCID: PMC4479394          DOI: 10.1097/MPH.0b013e318290c3b8

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  18 in total

1.  Primary cardiac sarcomas.

Authors:  J B Putnam; M S Sweeney; R Colon; L A Lanza; O H Frazier; D A Cooley
Journal:  Ann Thorac Surg       Date:  1991-06       Impact factor: 4.330

2.  High cumulative rate of secondary leukemia after continuous etoposide treatment for solid tumors in children and young adults.

Authors:  Marie-Cécile Le Deley; Gilles Vassal; Ahmed Taïbi; Akthar Shamsaldin; Thierry Leblanc; Olivier Hartmann
Journal:  Pediatr Blood Cancer       Date:  2005-07       Impact factor: 3.167

3.  Phase II study of 21 day schedule oral etoposide in children. New Agents Group of the United Kingdom Children's Cancer Study Group (UKCCSG).

Authors:  A Davidson; R Gowing; S Lowis; D Newell; I Lewis; C Dicks-Mireaux; C R Pinkerton
Journal:  Eur J Cancer       Date:  1997-10       Impact factor: 9.162

Review 4.  Therapy for primary cardiac tumors: is there a role for heart transplantation?

Authors:  A Gowdamarajan; R E Michler
Journal:  Curr Opin Cardiol       Date:  2000-03       Impact factor: 2.161

5.  Combined heart and lung transplantation for unresectable primary cardiac sarcoma.

Authors:  Susan M Talbot; Robert N Taub; Mary Lou Keohan; Niloo Edwards; Mark E Galantowicz; Larry L Schulman
Journal:  J Thorac Cardiovasc Surg       Date:  2002-12       Impact factor: 5.209

6.  Frequency of primary tumors of the heart.

Authors:  K Reynen
Journal:  Am J Cardiol       Date:  1996-01-01       Impact factor: 2.778

7.  Oral etoposide for recurrent/progressive sarcomas of childhood.

Authors:  Rejin Kebudi; Omer Görgün; Inci Ayan
Journal:  Pediatr Blood Cancer       Date:  2004-04       Impact factor: 3.167

8.  Risk of secondary leukemia after a solid tumor in childhood according to the dose of epipodophyllotoxins and anthracyclines: a case-control study by the Société Française d'Oncologie Pédiatrique.

Authors:  Marie-Cécile Le Deley; Thierry Leblanc; Akthar Shamsaldin; Marie-Anne Raquin; Brigitte Lacour; Danièle Sommelet; Agnès Chompret; Jean-Michel Cayuela; Chantal Bayle; Alain Bernheim; Florent de Vathaire; Gilles Vassal; Catherine Hill
Journal:  J Clin Oncol       Date:  2003-03-15       Impact factor: 44.544

9.  Heart transplantation: an approach to treating primary cardiac sarcoma?

Authors:  Peter Uberfuhr; Bruno Meiser; Alexandra Fuchs; Costas Schulze; Hermann Reichenspurner; Martin Falk; Max Weiss; Bernd Wintersperger; Rolf Issels; Bruno Reichart
Journal:  J Heart Lung Transplant       Date:  2002-10       Impact factor: 10.247

10.  Adjuvant chemotherapy for primary cardiac sarcomas: the IGR experience.

Authors:  A Llombart-Cussac; X Pivot; G Contesso; A Rhor-Alvarado; J P Delord; M Spielmann; T Türsz; A Le Cesne
Journal:  Br J Cancer       Date:  1998-12       Impact factor: 7.640

View more
  1 in total

1.  Primary cardiac sarcoma presenting as acute left-sided heart failure.

Authors:  Ranjan Pathak; Santosh Nepal; Smith Giri; Sushil Ghimire; Madan Raj Aryal
Journal:  J Community Hosp Intern Med Perspect       Date:  2014-07-31
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.